# Cellular Intelligence has secured global rights to Novo Nordisk's Parkinson's program.

*biotech · news · 2026-05-06 · FinanzNachrichten*

## Key points

- Cellular Intelligence has acquired global rights to Novo Nordisk's clinical-stage Parkinson's cell therapy.
- Cellular Intelligence will use its AI-native foundation model to accelerate development and lower manufacturing costs.
- Novo Nordisk will become an equity investor in Cellular Intelligence and retain future milestone and royalty options.
- The cell therapy is an allogeneic pluripotent stem cell-derived product currently in a Phase 1/2 trial with FDA Fast Track status.
- Data from the program will further train Cellular Intelligence's AI model for broader cell therapy and regenerative medicine applications.

**Companies:** Novo Nordisk, Cellular Intelligence
**Countries:** United States, Denmark

[Read the full story on FinanzNachrichten](https://www.finanznachrichten.de/nachrichten-2026-05/68456999-cellular-intelligence-an-ai-native-techbio-enters-agreement-with-novo-nordisk-to-advance-clinical-stage-parkinson-s-cell-therapy-008.htm)

---

Canonical: https://newsio.io/n/32b14b20-9ace-4f70-a29e-4e4fc6af6df8/cellular-intelligence-has-secured-global-rights-to-novo-nordisks-parkinsons-prog
Summarized by Newsio from FinanzNachrichten. https://newsio.io/how-it-works